Open-Label, Single Dose, Parallel Group Pharmacokinetic Study of Ceftobiprole in Morbidly Obese and Non-Obese Patients.

Trial Profile

Open-Label, Single Dose, Parallel Group Pharmacokinetic Study of Ceftobiprole in Morbidly Obese and Non-Obese Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Ceftobiprole medocaril (Primary)
  • Indications Enterococcal infections; Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections; Streptococcal infections
  • Focus Pharmacokinetics
  • Sponsors Basilea Pharmaceutica
  • Most Recent Events

    • 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
    • 27 Aug 2012 Company (Basilea Pharmaceutica) added as an association and lead centre as reported by ClinicalTrials.gov record.
    • 24 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top